Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan

Access this Article

Author(s)

    • Kanematsu Takanori
    • Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Toyoda Yuko
    • Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Goto Hisatsugu
    • Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Sakaguchi Satoshi
    • Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Kinoshita Katsuhiro
    • Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Azuma Momoyo
    • Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Kakiuchi Soji
    • Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Kishi Jun
    • Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Azuma Masahiko
    • Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Tada Hiroya
    • Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Hanibuchi Masaki
    • Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Nishioka Yasuhiko
    • Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Yano Seiji
    • Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School|Division of Medical Oncology, Cancer Research Institute, Kanazawa University
    • Sone Saburo
    • Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School|Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Tomimoto Hideki
    • Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Sakiyakma Shoji
    • Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Kenzaki Koichiro
    • Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Kondo Kazuya
    • Department of Oncological Medical Services, Institute of Health Biosciences, the University of Tokushima Gradate School
    • Bando Hiroyasu
    • Department of Respiratory Medicine, Tokushima Prefectural Central Hospital
    • Haku Takashi
    • Department of Respiratory Medicine, Tokushima Prefectural Central Hospital
    • Yoneda Kazuo
    • Department of Respiratory Medicine, Tokushima Prefectural Central Hospital

Abstract

Lung cancer is the leading cause of malignancy-related death worldwide. In the present study, we reviewed the epidemiologic and clinical features of lung cancer in Tokushima Prefecture, Japan. Between January 1999 and December 2009, 2,183 patients with lung cancer were enrolled in this study. One thousand five hundred ninety-one (73%) patients were male and 592 (27%) patients were female. Median age was 70 years, with a range of 15-93 years. Seventy-six percent of patients had smoking history. One thousand nine hundred five (87%) patients were non-small cell lung cancer and the predominant histological type was adenocarcinoma (51%). Among all 2,183 patients, 702 (32%) belonged to elderly population. Four hundred seventy-one (22%), 213 (10%), 24 (1%), 116 (5%), 238 (11%), 370 (17%) and 678 (31%) patients had stage IA, IB, IIA, IIB, IIIA, IIIB and IV lung cancer, respectively. In Tokushima University Hospital, 516 (29%), 191 (11%), 58 (3%), 755 (43%) and 216 (12%) patients were initially treated with chemotherapy, chemo-radiotherapy, thoracic radiotherapy, operation and best supportive care, respectively. The median time to progression (TTP) and the median survival time (MST) of patients treated with chemotherapy and chemo-radiotherapy were 3.5 months, 13.0 months and 7.0 months, 18.0 months, respectively. The median TTP and the MST of 33 elderly patients treated with chemotherapy were 3.3 months and 18.0 months, respectively, which were comparable with those of total population. These results indicated the benefit of chemotherapy in elderly patients with advanced lung cancer by proper selection. J. Med. Invest. 57: 326-333, August, 2010

Journal

  • The Journal of Medical Investigation

    The Journal of Medical Investigation 57(3,4), 326-333, 2010

    The University of Tokushima Faculty of Medicine

Codes

  • NII Article ID (NAID)
    130004465225
  • Text Lang
    ENG
  • ISSN
    1343-1420
  • Data Source
    J-STAGE 
Page Top